

HR 2315

Preserving Access to Orphan Drugs Act of 2013

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 11, 2013

Current Status: Rereferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commer

Latest Action: Rereferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Jul 25, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/2315>

Sponsor

Name: Rep. Gerlach, Jim [R-PA-6]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors (53 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Neal, Richard E. [D-MA-1]	D · MA		Jun 11, 2013
Rep. Burgess, Michael C. [R-TX-26]	R · TX		Jun 20, 2013
Rep. McKinley, David B. [R-WV-1]	R · WV		Jul 9, 2013
Rep. Carson, Andre [D-IN-7]	D · IN		Jul 10, 2013
Rep. Schwartz, Allyson Y. [D-PA-13]	D · PA		Jul 10, 2013
Rep. Thompson, Glenn [R-PA-5]	R · PA		Jul 16, 2013
Rep. Kinzinger, Adam [R-IL-16]	R · IL		Jul 17, 2013
Rep. Paulsen, Erik [R-MN-3]	R · MN		Jul 24, 2013
Rep. Polis, Jared [D-CO-2]	D · CO		Jul 30, 2013
Rep. Griffin, Tim [R-AR-2]	R · AR		Jul 31, 2013
Rep. Murphy, Patrick [D-FL-18]	D · FL		Aug 2, 2013
Rep. Owens, William L. [D-NY-21]	D · NY		Aug 2, 2013
Rep. Perlmutter, Ed [D-CO-7]	D · CO		Aug 2, 2013
Rep. Engel, Eliot L. [D-NY-16]	D · NY		Sep 10, 2013
Rep. Nunes, Devin [R-CA-22]	R · CA		Sep 10, 2013
Rep. Rangel, Charles B. [D-NY-13]	D · NY		Sep 10, 2013
Rep. Kelly, Mike [R-PA-3]	R · PA		Sep 18, 2013
Rep. Jenkins, Lynn [R-KS-2]	R · KS		Sep 23, 2013
Rep. Meehan, Patrick [R-PA-7]	R · PA		Sep 23, 2013
Rep. Guthrie, Brett [R-KY-2]	R · KY		Oct 2, 2013
Rep. Lance, Leonard [R-NJ-7]	R · NJ		Oct 8, 2013
Rep. McMorris Rodgers, Cathy [R-WA-5]	R · WA		Oct 8, 2013
Rep. Marchant, Kenny [R-TX-24]	R · TX		Oct 10, 2013
Rep. Young, Todd [R-IN-9]	R · IN		Oct 16, 2013
Rep. Kind, Ron [D-WI-3]	D · WI		Nov 13, 2013
Rep. McCaul, Michael T. [R-TX-10]	R · TX		Nov 13, 2013
Rep. Pompeo, Mike [R-KS-4]	R · KS		Nov 13, 2013
Rep. Renacci, James B. [R-OH-16]	R · OH		Nov 13, 2013
Rep. Wolf, Frank R. [R-VA-10]	R · VA		Nov 13, 2013
Rep. Latham, Tom [R-IA-3]	R · IA		Nov 14, 2013
Rep. Dent, Charles W. [R-PA-15]	R · PA		Nov 15, 2013
Rep. Rokita, Todd [R-IN-4]	R · IN		Dec 12, 2013
Rep. Brooks, Susan W. [R-IN-5]	R · IN		Jan 21, 2014
Rep. Frankel, Lois [D-FL-22]	D · FL		Jan 21, 2014
Rep. Boustany, Charles W., Jr. [R-LA-3]	R · LA		Feb 26, 2014
Rep. Nolan, Richard M. [D-MN-8]	D · MN		Feb 26, 2014
Rep. Schrader, Kurt [D-OR-5]	D · OR		Feb 27, 2014
Rep. Cohen, Steve [D-TN-9]	D · TN		Mar 6, 2014
Rep. Loebsack, David [D-IA-2]	D · IA		Mar 11, 2014
Rep. Tiberi, Patrick J. [R-OH-12]	R · OH		Mar 21, 2014
Rep. Johnson, Eddie Bernice [D-TX-30]	D · TX		Mar 24, 2014

Cosponsor	Party / State	Role	Date Joined
Rep. King, Peter T. [R-NY-2]	R · NY		Mar 25, 2014
Rep. Gibson, Christopher P. [R-NY-19]	R · NY		Apr 2, 2014
Rep. Johnson, Bill [R-OH-6]	R · OH		Apr 10, 2014
Rep. Black, Diane [R-TN-6]	R · TN		May 1, 2014
Rep. Murphy, Tim [R-PA-18]	R · PA		May 8, 2014
Rep. Rothfus, Keith J. [R-PA-12]	R · PA		May 20, 2014
Rep. Schock, Aaron [R-IL-18]	R · IL		May 28, 2014
Rep. Long, Billy [R-MO-7]	R · MO		May 29, 2014
Rep. Jolly, David [R-FL-13]	R · FL		Jul 8, 2014
Rep. Shimkus, John [R-IL-15]	R · IL		Jul 10, 2014
Rep. Thompson, Mike [D-CA-5]	D · CA		Sep 8, 2014
Rep. Bishop, Timothy H. [D-NY-1]	D · NY		Sep 18, 2014

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 14, 2013
Ways and Means Committee	House	Re-Referred to	Jul 25, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 S 1128	Identical bill	Jun 11, 2013: Read twice and referred to the Committee on Finance.

Summary (as of Jun 11, 2013)

Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding \$5 million.

Makes this Act effective as if included in PPACA.

Actions Timeline

- **Jul 25, 2013:** Rereferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Jun 14, 2013:** Referred to the Subcommittee on Health.
- **Jun 11, 2013:** Introduced in House
- **Jun 11, 2013:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.